AR and prostate cancer: In addition, the overexpression of JAG1 and JICD in PPC-1 cells (AR-negative PC-3-derived prostate cancer cells) markedly enhanced the androgen-dependent and androgen-independent transactivation of exogenous AR-FL, AR-NTD-DBD, and AR-V7 in a dose-dependent manner (Figure 3D–F and Figure S2).